MELANOMA (SKIN CANCER)

This study tests whether adding two oral drugs (AMXT 1501 and DFMO) to standard treatments can help people with advanced solid tumors that have stopped responding to prior therapies. The trial includes two groups: one with a type of breast cancer and another with melanoma. The go…

This study tests a new oral drug, LNS8801, alone or combined with the immunotherapy pembrolizumab, in people with advanced melanoma that has stopped responding to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plu…

This study tests whether people with early-stage melanoma can safely avoid a second surgery (re-excision) after the initial tumor is removed. About 1,749 patients will be randomly assigned to either standard re-excision or no further surgery. The goal is to see if skipping re-exc…

This early-phase trial tests whether combining cadonilimab with high-dose interferon before surgery can shrink tumors in people with stage III or IV melanoma. About 10 participants will receive the treatment and be monitored for side effects and tumor response. The goal is to gat…

This early-phase study is testing a combination of two drugs, alpelisib and pembrolizumab, in people with metastatic breast cancer or melanoma that has spread to the brain. The main goal is to find a safe dose and check for side effects. About 50 adults whose cancer has not respo…

This early-stage study tests a new drug called TGI-5, alone or with another drug (nivolumab), in people with advanced solid tumors like colorectal, liver, melanoma, and lung cancer. The main goals are to check safety and find the right dose. About 194 adults will take part. This …

This study tests if a low-protein diet (low in branched-chain amino acids) combined with an immunotherapy drug (anti-PD-1) is safe and effective for people with stage III melanoma. About 80 participants will receive the diet and drug before surgery. Researchers will monitor side …

This study tests a new treatment called EBNK-001, which uses donor immune cells (natural killer cells) to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive these cells alon…

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This study is testing whether giving a single dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the immune system fight high-risk melanoma more effectively. It includes 49 adults with melanoma that hasn't spread on scans. After surgery, some patients …

This study tests whether one dose of the immunotherapy drug pembrolizumab, given before standard surgery, can shrink or eliminate tumors in people with stage IIb/c melanoma. About 30 adults with thick melanomas that haven't spread to lymph nodes will receive either pembrolizumab …

This study collects tumor samples from 2,000 people with various cancers to learn how to predict who will respond to immunotherapy. Participants donate tissue during a routine biopsy. The goal is to understand tumor biology and improve future treatment decisions, not to test a ne…

This study involves 200 adults with suspicious skin moles that are already scheduled for removal. Researchers will use a special microscope (reflectance confocal microscopy) to take detailed images of the moles before surgery, then compare those images with genetic tests done on …

This study looks at how certain immunotherapy drugs (called immune checkpoint inhibitors) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers in 25 patients over a year to see if these treatments increase fracture risk.…

This study looks at how immune checkpoint inhibitor (ICI) treatment for melanoma affects reproductive organs and sex hormones. Researchers will collect blood samples and questionnaires from 80 participants during their regular treatment visits. Men will also provide semen samples…

This study is building a platform to better predict who is at risk for developing or having a recurrence of certain cancers, including breast, colon, ovarian, melanoma, and lung cancer. Researchers will analyze participants' blood and genetic information to find markers that coul…

This study looks at blood samples from 20 people with melanoma or other skin cancers to see if certain markers in the blood can predict how well treatment works or how long patients live. Participants give blood during their regular care. The goal is to find better ways to monito…

This study is looking at blood samples from 200 people with melanoma to find markers that can help doctors track how well treatment is working. Participants will give blood before and during standard immunotherapy, and have scans every 12 weeks. The goal is to develop a simple bl…